1252 related articles for article (PubMed ID: 33972366)
1. Viral Proteases as Targets for Coronavirus Disease 2019 Drug Development.
Zhu W; Shyr Z; Lo DC; Zheng W
J Pharmacol Exp Ther; 2021 Aug; 378(2):166-172. PubMed ID: 33972366
[TBL] [Abstract][Full Text] [Related]
2. Targeting SARS-CoV-2 viral proteases as a therapeutic strategy to treat COVID-19.
Anirudhan V; Lee H; Cheng H; Cooper L; Rong L
J Med Virol; 2021 May; 93(5):2722-2734. PubMed ID: 33475167
[TBL] [Abstract][Full Text] [Related]
3. Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection.
Dampalla CS; Zheng J; Perera KD; Wong LR; Meyerholz DK; Nguyen HN; Kashipathy MM; Battaile KP; Lovell S; Kim Y; Perlman S; Groutas WC; Chang KO
Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34210738
[TBL] [Abstract][Full Text] [Related]
4. A low-background, fluorescent assay to evaluate inhibitors of diverse viral proteases.
Leonard RA; Rao VN; Bartlett A; Froggatt HM; Luftig MA; Heaton BE; Heaton NS
J Virol; 2023 Aug; 97(8):e0059723. PubMed ID: 37578235
[TBL] [Abstract][Full Text] [Related]
5. Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit.
Hall MD; Anderson JM; Anderson A; Baker D; Bradner J; Brimacombe KR; Campbell EA; Corbett KS; Carter K; Cherry S; Chiang L; Cihlar T; de Wit E; Denison M; Disney M; Fletcher CV; Ford-Scheimer SL; Götte M; Grossman AC; Hayden FG; Hazuda DJ; Lanteri CA; Marston H; Mesecar AD; Moore S; Nwankwo JO; O'Rear J; Painter G; Singh Saikatendu K; Schiffer CA; Sheahan TP; Shi PY; Smyth HD; Sofia MJ; Weetall M; Weller SK; Whitley R; Fauci AS; Austin CP; Collins FS; Conley AJ; Davis MI
J Infect Dis; 2021 Jul; 224(Supplement_1):S1-S21. PubMed ID: 34111271
[TBL] [Abstract][Full Text] [Related]
6. Computational Selectivity Assessment of Protease Inhibitors against SARS-CoV-2.
Fischer A; Sellner M; Mitusińska K; Bzówka M; Lill MA; Góra A; Smieško M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669738
[TBL] [Abstract][Full Text] [Related]
7. Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
Cannalire R; Cerchia C; Beccari AR; Di Leva FS; Summa V
J Med Chem; 2022 Feb; 65(4):2716-2746. PubMed ID: 33186044
[TBL] [Abstract][Full Text] [Related]
8. Characterising proteolysis during SARS-CoV-2 infection identifies viral cleavage sites and cellular targets with therapeutic potential.
Meyer B; Chiaravalli J; Gellenoncourt S; Brownridge P; Bryne DP; Daly LA; Grauslys A; Walter M; Agou F; Chakrabarti LA; Craik CS; Eyers CE; Eyers PA; Gambin Y; Jones AR; Sierecki E; Verdin E; Vignuzzi M; Emmott E
Nat Commun; 2021 Sep; 12(1):5553. PubMed ID: 34548480
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture.
Bafna K; White K; Harish B; Rosales R; Ramelot TA; Acton TB; Moreno E; Kehrer T; Miorin L; Royer CA; García-Sastre A; Krug RM; Montelione GT
Cell Rep; 2021 May; 35(7):109133. PubMed ID: 33984267
[TBL] [Abstract][Full Text] [Related]
10. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
[TBL] [Abstract][Full Text] [Related]
11. High-Throughput Screening for Drugs That Inhibit Papain-Like Protease in SARS-CoV-2.
Smith E; Davis-Gardner ME; Garcia-Ordonez RD; Nguyen TT; Hull M; Chen E; Baillargeon P; Scampavia L; Strutzenberg T; Griffin PR; Farzan M; Spicer TP
SLAS Discov; 2020 Dec; 25(10):1152-1161. PubMed ID: 33043784
[TBL] [Abstract][Full Text] [Related]
12. Bioactive Terpenes and Their Derivatives as Potential SARS-CoV-2 Proteases Inhibitors from Molecular Modeling Studies.
Diniz LRL; Perez-Castillo Y; Elshabrawy HA; Filho CDSMB; de Sousa DP
Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33430299
[TBL] [Abstract][Full Text] [Related]
13. Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review.
Al-Horani RA; Kar S
Viruses; 2020 Sep; 12(10):. PubMed ID: 32993173
[TBL] [Abstract][Full Text] [Related]
14. Comparative Antiviral Efficacy of Viral Protease Inhibitors against the Novel SARS-CoV-2 In Vitro.
Zhang L; Liu J; Cao R; Xu M; Wu Y; Shang W; Wang X; Zhang H; Jiang X; Sun Y; Hu H; Li Y; Zou G; Zhang M; Zhao L; Li W; Guo X; Zhuang X; Yang XL; Shi ZL; Deng F; Hu Z; Xiao G; Wang M; Zhong W
Virol Sin; 2020 Dec; 35(6):776-784. PubMed ID: 32910347
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease.
Kronenberger T; Laufer SA; Pillaiyar T
Drug Discov Today; 2023 Jun; 28(6):103579. PubMed ID: 37028502
[TBL] [Abstract][Full Text] [Related]
16. Overview of antiviral drug candidates targeting coronaviral 3C-like main proteases.
Chen CC; Yu X; Kuo CJ; Min J; Chen S; Ma L; Liu K; Guo RT
FEBS J; 2021 Sep; 288(17):5089-5121. PubMed ID: 33400393
[TBL] [Abstract][Full Text] [Related]
17. Protease inhibitors targeting the main protease and papain-like protease of coronaviruses.
Capasso C; Nocentini A; Supuran CT
Expert Opin Ther Pat; 2021 Apr; 31(4):309-324. PubMed ID: 33246378
[TBL] [Abstract][Full Text] [Related]
18. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
[TBL] [Abstract][Full Text] [Related]
19. TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).
Lee J; Lee J; Kim HJ; Ko M; Jee Y; Kim S
Microbiol Spectr; 2021 Sep; 9(1):e0047221. PubMed ID: 34378968
[TBL] [Abstract][Full Text] [Related]
20. Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.
Khare P; Sahu U; Pandey SC; Samant M
Virus Res; 2020 Dec; 290():198169. PubMed ID: 32979476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
